Trending...
- DriveYo Signs Cybersecurity Prodigy and Open-Source Pioneer Utkarsh Lubal
- Eric Bellinger Debuts "Cry In Front Of You" Live Following Tamla Motown Signing
- Rabbi Michael Rothschild (#ViralRabbi) to Discuss Futurism on the Popular "The Mike Holt Show"
Presentation will highlight this novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, Calif. - Californer -- Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, will present on its patent-pending therapeutic agent, CTZ1™, at the OIS XII event on December 2nd in San Diego, CA. CTZ1™ is the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and dry AMD and was selected for this most competitive showcase for emerging ophthalmology and retina therapeutics and devices.
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email salkayali@citrustherapeutics.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
- Mac Mountain Selects netElastic vRouter for LightCraft Broadband-as-a-Service Platform
- A Kickstarter Campaign for "A Cable To The Moon"
- California Watermelon Festival "A Sweet Slice of California"
- Oceanside Bombers Team Up with Bragabilia Energy for Limited‑Edition "Quiet Flex" Cans
- Frequent Coffee Sets New Record with 94-Point Decaf Score
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email salkayali@citrustherapeutics.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Source: Citrus Therapeutics
Filed Under: Medical
0 Comments
Latest on The Californer
- PasskeyBridge Launches Patent-Pending Identity Threat Response Platform With Zero PII Storage
- Economist N. Robert Branch to Headline Summit for Economic Liberalism; Target 10,000 LA Attendees
- EXCLUSIVE: Slam City's Speed Shift Origins Gains Financing and Distribution Momentum; Mike Ryan Joins as Stunt Director
- Filmmaker Domenic Migliore Announces Anthology Series "Evermore: Tales from the Mind of Poe"
- Actor Cody Derr Announces New Representation
- Studio City Fitness Expert Leo Frincu Releases "The Survival Blueprint"
- ICYMI: Bloomberg News: How California's economy dominates in the Gavin Newsom era
- City of Long Beach Unveils Design for Cambodia Town Grand Entrance
- Long Beach Health Department Marks 120 Years of Public Health Service During National Public Health Week
- Game Day Private Jets Launches REVUP Platform to Transform Fan & Donor Travel Into a Revenue Engine for College Athletics
- Heritage at South Brunswick Team Celebrates Major Wins at NJBA Sales and Marketing Awards
- Dr. Angela Butts Chester Named Contributor to Elon University's 2026 AI Resilience Report
- California Film & TV Tax Credit powers 55 major award wins during Governor Newsom's Administration
- InterMountain Announces the Opening of TownePlace Suites Reno
- SnapTax Launches AI-Powered Tax Planning Platform for Freelancers and 1099 Workers — Now Free for 90 Days
- MAG Magna Corp Targets Trillion-Dollar Opportunity by Tokenizing Rare Earth Assets Critical to AI, EVs, & Defense: MAG Magna Corp.: Stock Symbol: MGNC
- Congressional Roundtable Exposes Mental Health Crisis: More Spending and Treatment, Worse Results – CCHR Demands Accountability
- Matter Studio Gallery Presents Evolving Matter at The Pavilion Century City
- Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking
- NAIDOC Week Australia 2026 | 50 Years Deadly - Celebrates Culture, Resilience, and Global Connection